Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

The actress and entertainment personality partnered with Amgen to share candid glimpses of how she lives with her medical ...

plaque psoriasis Guttate psoriasis isn’t as common ... psoriasis if they have an autoimmune disorder like rheumatoid arthritis or are undergoing chemotherapy. Smoking tobacco also raises ...

US FDA approves UCB’s 320 mg single-injection device presentations of Bimzelx: Brussels, Belgium Tuesday, October 15, 2024, 13:00 Hrs [IST] UCB, a global biopharmaceutical compa ...

Research on the role that genes play in psoriasis has led to targeted therapies to reduce symptoms and slow disease ...

Dermatologists recently have developed and validated several tools for assessing itch in plaque psoriasis, such as the Peak ...

La La Anthony took to Instagram to share her personal struggle with plaque psoriasis, a chronic autoimmune condition that ...

Imuldosa is the latest FDA-approved biosimilar of J&J’s blockbuster therapy for the treatment of certain autoimmune diseases.

“The heroes here tonight are not make-believe heroes from Marvel Comics, but real-life heroes who have made an impact on ...

Thousand Oaks, California Friday, October 4, 2024, 14:00 Hrs [IST] ...

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.